Uropathogen resistance in kidney transplant recipients climbed from 40.1% to 53.4% over ten years, and the dominant organism switched from Escherichia coli to Klebsiella pneumoniae. A single-center review of 491 recipients and 448 urinary tract infection episodes, published on 30 September 2026, tracked both changes across two five-year periods and found the immunosuppression regimen moving at the same time.
Why transplant urology changed over a decade
Urinary tract infection is the most common infection after kidney transplantation, and it is not one disease. Asymptomatic bacteriuria needs no treatment in most patients. Acute graft pyelonephritis puts the graft at risk. Urosepsis puts the patient at risk. Averaging them together hides the part that matters.
The transplant population itself moved between 2013 and 2022. Recipients got older, human leukocyte antigen mismatches increased, and induction therapy became routine. Every one of those changes alters the infection risk profile. The review asked whether the microbiology moved with them, and if so, how far.
The answer has direct consequences for empiric prescribing. When a transplant recipient arrives with fever and flank pain, the antibiotic chosen before cultures return depends on which organisms dominate that center and how resistant they have become. A protocol written in 2015 may be the wrong protocol for 2022.
The cohort and how episodes were counted
| Parameter | Value |
|---|---|
| Study period | January 2013 to December 2022 |
| Design | Single-center retrospective analysis |
| Transplants performed | 1,075 |
| Recipients analyzed | 491 |
| Recipients with at least one urinary tract infection | 187 |
| Total urinary tract infection episodes | 448 |
| Patients with asymptomatic bacteriuria only | 66 |
| Patients with symptomatic infection | 121 |
| Patients with recurrent symptomatic infection | 57 |
| Follow-up window | first year after transplantation |
| Urine culture schedule | weekly during the first month |
Recipients were excluded if they moved to another center, went back on dialysis, or died within the first year from a cause unrelated to urinary infection. Perioperative prophylaxis was ceftriaxone for four days, then trimethoprim and sulfamethoxazole at 80 and 400 mg daily by mouth for six months, given mainly to prevent Pneumocystis pneumonia. The trimethoprim component also covers many uropathogens, which is part of why late infections behave differently from early ones.
Episode types and when they appear
| Episode type | Count | Share of 448 |
|---|---|---|
| Asymptomatic bacteriuria | 211 | 47% |
| Lower urinary tract infection | 80 | 18% |
| Acute graft pyelonephritis | 97 | 22% |
| Urosepsis | 60 | 13% |
The distribution leans toward the benign end, and timing explains much of it. More than 69% of episodes in the first month after transplantation were asymptomatic bacteriuria. From the second month on, that share dropped to about 40%. Early bacteriuria is largely a byproduct of the catheter and the surgery. Late bacteriuria is a different problem and calls for a different response.
Rates of the serious categories held steady. Acute graft pyelonephritis accounted for 41 episodes (19%) in 2013 to 2017 and 56 episodes (24%) in 2018 to 2022, p = 0.25. Urosepsis accounted for 25 (12%) and 35 (15%), p = 0.33. Neither shift reached significance. The overall burden of any urinary tract infection, asymptomatic bacteriuria included, was 41% of recipients in the earlier period and 36% in the later one, p = 0.26.
So infection volume did not rise. What changed was who caused it and how well the drugs still worked.
Immunosuppression shifted before the pathogens did
| Regimen | 2013 to 2017 (n = 217) | 2018 to 2022 (n = 274) | p |
|---|---|---|---|
| Mycophenolate mofetil or sodium | 212 (97.7%) | 274 (100.0%) | 0.02 |
| Tacrolimus | 131 (60.4%) | 239 (87.2%) | under 0.001 |
| Cyclosporine | 82 (37.8%) | 35 (12.8%) | under 0.001 |
| Antithymocyte globulin induction | 40 (18.4%) | 107 (39.1%) | under 0.001 |
| Basiliximab induction | 64 (29.5%) | 112 (40.9%) | 0.01 |
| Any induction therapy | 104 (47.9%) | 213 (77.7%) | under 0.001 |
Across the whole cohort, mycophenolate mofetil or mycophenolate sodium was used in 486 of 491 recipients, or 98.98%. Tacrolimus reached 370 of 491, or 75.36%, with an annual odds ratio of 1.28 and a 95% confidence interval of 1.19 to 1.39. Cyclosporine covered 117 of 491, or 23.83%. Antithymocyte globulin induction reached 147 of 491, or 29.94%, annual odds ratio 1.31, interval 1.21 to 1.42. Basiliximab reached 176 of 491, or 35.85%, annual odds ratio 1.09, interval 1.02 to 1.17. Any induction therapy reached 317 of 491, or 64.56%.
Two things stand out. Mycophenolate is effectively universal in this population, so any infection-control strategy after kidney transplantation has to assume it is on board. And induction therapy went from under half of recipients to more than three quarters inside ten years. More intense immunosuppression alongside rising uropathogen resistance is a correlation rather than a proven cause, but it is a correlation worth watching.
Recipient characteristics moved too. Mean age was 47.97 years in the earlier period and 48.65 in the later one, p = 0.717. Recipients aged 70 or over rose from 5, or 2%, to 16, or 6%, p = 0.07. Those aged 75 or over went from none to 5, or 2%, p = 0.07. Mean human leukocyte antigen mismatches rose from 2.71 to 3.03, p = 0.001. Maximum calculated panel reactive antibody rose from 5.54 to 7.39, p = 0.001. Warm ischemia time rose from 27.56 to 32.82 minutes, p under 0.001. Mean hospital stay fell from 20.13 to 16.89 days, p under 0.001. Documented cytomegalovirus infection fell from 85 patients, or 39.2%, to 71, or 25.9%, p = 0.002.
The pathogen shift: E. coli to Klebsiella pneumoniae
| Organism | Total isolates across the cohort |
|---|---|
| Klebsiella pneumoniae | 153 |
| Escherichia coli | 121 |
| Enterococcus faecium | 47 |
| Enterococcus faecalis | 43 |
| Other | remainder |
Escherichia coli caused almost 35% of all episodes in 2013 to 2017. By 2018 to 2022, Klebsiella pneumoniae had taken the lead at 45% of episodes.
| Organism | Annual odds ratio (95% CI) | p |
|---|---|---|
| Klebsiella pneumoniae, all episodes | 1.23 (1.08 to 1.39) | 0.0018 |
| Klebsiella pneumoniae, symptomatic episodes | 1.28 (1.12 to 1.46) | under 0.001 |
| Enterococcus faecium, symptomatic episodes | 0.75 (0.60 to 0.93) | 0.0080 |
| Escherichia coli, all episodes | 0.91 (0.81 to 1.02) | 0.1067 |
The Klebsiella trend is the one that matters. An annual odds ratio of 1.23 compounds, so over five years the odds of Klebsiella as the culprit roughly double. Escherichia coli showed a declining but non-significant trend, annual odds ratio 0.91, with a confidence interval crossing 1.
The organism also depended on the syndrome. Urosepsis was still dominated by Escherichia coli. Asymptomatic bacteriuria, cystitis, and acute graft pyelonephritis were dominated by Klebsiella pneumoniae. That split has a practical consequence. If a transplant recipient is septic, empiric coverage should still handle Escherichia coli well. A non-septic presentation with pyuria is more likely to be Klebsiella and more likely to carry resistance mechanisms.
Uropathogen resistance climbed in step
| Resistance measure | Value |
|---|---|
| Episodes caused by highly resistant strains | 212 |
| Extended-spectrum beta-lactamase producing Enterobacteriaceae | 185 |
| Vancomycin-resistant Enterococcus faecium | 13 |
| Carbapenemase-producing Klebsiella pneumoniae | 14 |
| Of which metallo-beta-lactamase VIM type | 10 |
| Symptomatic episodes caused by highly resistant strains | 115 of 237 (48.5%) |
| Patients with at least one highly resistant infection | 61 of 121 (over 50%) |
| Period | Share of isolates that were highly resistant |
|---|---|
| 2013 to 2017 | 40.1% |
| 2018 to 2022 | 53.4%, p = 0.008 |
The linear model put the annual odds ratio for a highly resistant phenotype at 1.12, interval 1.01 to 1.25, p = 0.0369. For extended-spectrum beta-lactamase producers in symptomatic episodes the annual odds ratio was 1.13, interval 1.01 to 1.26, p = 0.0353. Highly resistant strains in symptomatic episodes moved from 42% to 54.5%, p = 0.07, which is a trend rather than a confirmed change.
Almost every carbapenemase-producing isolate appeared in 2022, with one exception. Fourteen cases is a small absolute number, but concentrating them in a single year is the kind of signal that precedes a durable problem. Metallo-beta-lactamase VIM strains accounted for 10 of the 14, and that enzyme class falls outside the spectrum of the newer beta-lactam and beta-lactamase inhibitor combinations that handle many serine carbapenemases. A center seeing VIM-producing Klebsiella has to plan for it specifically.
Enterococcus ran the other way. Enterococcus faecium in symptomatic episodes fell, annual odds ratio 0.75, interval 0.60 to 0.93, p = 0.0080. Vancomycin-resistant Enterococcus still appeared in 13 episodes, so the decline does not mean the problem is gone.
Who is at risk
| Factor | Adjusted odds ratio (95% CI) | p |
|---|---|---|
| Female sex | 2.38 (1.48 to 3.81) | under 0.001 |
| Urinary flow obstruction | 3.91 (2.24 to 6.82) | under 0.001 |
| Hospital stay, per day | 1.05 (1.03 to 1.08) | under 0.001 |
| Charlson comorbidity index, per point | 1.05 (0.92 to 1.20) | 0.4791 |
| Factor | Adjusted incidence rate ratio (95% CI) | p |
|---|---|---|
| Female sex | 1.92 (1.28 to 2.88) | 0.0016 |
| Urinary flow obstruction | 4.09 (2.57 to 6.51) | under 0.001 |
| Hospital stay, per day | 1.03 (1.01 to 1.05) | under 0.001 |
| Charlson comorbidity index, per point | 1.01 (0.90 to 1.14) | 0.8110 |
Urinary flow obstruction is the largest and most actionable factor. It carried an adjusted odds ratio of 3.91 for symptomatic infection and an adjusted incidence rate ratio of 4.09 for episode count. Among patients with recurrent infections, 52% had a structural obstruction: prostatic enlargement, vesicoureteral reflux, or ureterovesical junction stenosis. Those patients were also older, 55.8 years against 46.8 years, p under 0.001.
Several univariate factors fell away once adjusted. Delayed graft function carried an odds ratio of 1.96, interval 1.26 to 3.04, p = 0.003 on its own and did not survive adjustment. Warm ischemia time carried an odds ratio of 1.03, interval 1.003 to 1.05, p = 0.03. Longer dialysis vintage carried an odds ratio of 1.01, interval 1.001 to 1.02, p = 0.03. Antithymocyte globulin induction carried an odds ratio of 1.71, interval 1.11 to 2.64, p = 0.02. Retransplantation, high panel reactive antibody, and body mass index never emerged as risk factors.
Cytomegalovirus infection sat on the boundary. It appeared in 38.8% of patients with symptomatic urinary infection against 29.5% of those without, p = 0.057. That is suggestive rather than established, and it fits the broader idea that the overall intensity of immunosuppression and viral co-infection shapes bacterial risk.
What the CMV and prophylaxis data add
Cytomegalovirus infection fell from 39.2% to 25.9% of recipients between the two periods, p = 0.002, even as induction therapy intensified. Antiviral prophylaxis and monitoring protocols tightened across the same decade, and the timing of the fall suggests those efforts worked. Valganciclovir remains the standard oral agent for cytomegalovirus prevention and treatment in this population, dosed on renal function, which is unstable in the weeks after transplantation.
Urinary prophylaxis is doing double duty. The six-month trimethoprim and sulfamethoxazole course prevents Pneumocystis pneumonia and suppresses many uropathogens during the highest-risk months. When it stops, the uropathogen mix can shift. That may partly explain why late infections were more often Klebsiella and more often resistant, since the drug exerts selection pressure on the organisms it does not fully suppress.
One death occurred in the ten-year window, a patient who died of Klebsiella pneumoniae urosepsis within the first year. No donor-derived urinary infection was recorded.
What this means in practice
- Rewrite empiric urinary antibiotic guidance for transplant recipients on a schedule instead of letting it drift. The dominant organism changed and the resistance rate changed with it. A protocol older than a few years describes a different population.
- Separate septic from non-septic presentations when choosing empiric coverage. Urosepsis here remained dominated by Escherichia coli, while asymptomatic bacteriuria, cystitis, and acute graft pyelonephritis were dominated by Klebsiella pneumoniae.
- Ask explicitly about metallo-beta-lactamase VIM producers when reading local antibiograms. Ten of the fourteen carbapenemase-producing Klebsiella isolates carried that enzyme, and it falls outside the spectrum of several newer beta-lactam combinations.
- Investigate and relieve urinary flow obstruction in any recipient with recurrent infections. It carried the largest adjusted effect in the model, an adjusted odds ratio of 3.91, and 52% of recurrent cases had a structural cause that can often be corrected.
- Do not treat asymptomatic bacteriuria reflexively, particularly in the first month. It accounted for 47% of all episodes and more than 69% of first-month episodes, where it largely reflects catheterization. Antibiotic exposure in that window selects for exactly the resistance patterns the later years show.
- Expect mycophenolate to be in every regimen. It was used in 98.98% of the cohort, so any drug interaction review and any infection risk assessment starts there.
- Keep cytomegalovirus surveillance tight. Viral co-infection tracked with symptomatic urinary infection at p = 0.057, and the decade-long fall in cytomegalovirus infection shows that prophylaxis intensity does change outcomes.
Limitations
The review is retrospective and comes from one center, so the microbiology reflects a single catchment area and a single antibiotic stewardship culture. Roughly half of the recipients transferred to other follow-up centers after the first month, which caps how completely late infections were captured. The analysis left Pseudomonas aeruginosa and Proteus mirabilis out of the pathogen breakdown. Confounders including pre-transplant urinary infection history and sexual activity were not assessed. The two five-year periods were compared with unadjusted and adjusted models, but a decade-long secular trend in antibiotic use outside the transplant program cannot be separated from the transplant-specific changes.
The mycophenolate figure of 98.98% is close enough to universal that the drug cannot be analyzed as a risk factor within this cohort. Comparing mycophenolate against other maintenance agents would need a population where both are used.
Finally, uropathogen resistance is measured here at a single center, and antibiograms differ substantially between hospitals. The absolute resistance percentages will not transfer. The direction of travel, and the organisms driving it, are more portable than the numbers.
Bottom line
Over ten years in one transplant center, the burden of urinary tract infection stayed roughly flat at 36% to 41% of recipients, but its microbiology changed. Klebsiella pneumoniae overtook Escherichia coli and reached 45% of episodes by 2018 to 2022, annual odds ratio 1.23. Uropathogen resistance rose from 40.1% to 53.4% of isolates, and 48.5% of symptomatic episodes involved highly resistant strains. Ten of fourteen carbapenemase-producing Klebsiella isolates carried a VIM metallo-beta-lactamase. Immunosuppression intensified in parallel, with induction therapy rising from 47.9% to 77.7% and tacrolimus from 60.4% to 87.2%, against mycophenolate use at 98.98%. Urinary flow obstruction remained the strongest modifiable risk factor, and cytomegalovirus infection fell from 39.2% to 25.9% as prophylaxis tightened.
FAQ
What is uropathogen resistance in kidney transplant recipients
Uropathogen resistance describes how many bacteria causing urinary infection in transplant recipients withstand the antibiotics normally used against them. In a 491-recipient cohort the share of highly resistant isolates rose from 40.1% between 2013 and 2017 to 53.4% between 2018 and 2022, a difference with p = 0.008.
Which bacteria now cause most urinary infections after kidney transplantation
Klebsiella pneumoniae took the lead. It caused 45% of episodes in 2018 to 2022, up from a period when Escherichia coli caused almost 35%. Across the whole cohort Klebsiella accounted for 153 isolates, Escherichia coli for 121, Enterococcus faecium for 47, and Enterococcus faecalis for 43, which shows how far the mix moved from the older Escherichia coli dominance.
How often does urosepsis occur after kidney transplantation
Urosepsis accounted for 60 of 448 episodes, or 13%, in this cohort. The rate was stable across periods, 25 episodes or 12% between 2013 and 2017 against 35 episodes or 15% between 2018 and 2022, with p = 0.33. Unlike other syndromes, urosepsis remained dominated by Escherichia coli rather than Klebsiella.
Should asymptomatic bacteriuria be treated in transplant recipients
Usually not. Asymptomatic bacteriuria accounted for 211 of 448 episodes, or 47%, and for more than 69% of first-month episodes where catheterization is the main driver. Treating it exposes patients to antibiotics that select for resistance without clearing the underlying colonization. Later months were different, with bacteriuria falling to about 40% of episodes.
What is the strongest risk factor for recurrent urinary infection after transplant
Urinary flow obstruction. It carried an adjusted odds ratio of 3.91, interval 2.24 to 6.82, for symptomatic infection and an adjusted incidence rate ratio of 4.09 for episode count. Among patients with recurrent infections, 52% had a structural cause such as prostatic enlargement, vesicoureteral reflux, or ureterovesical junction stenosis.
Which immunosuppressant do most kidney transplant recipients take
Mycophenolate mofetil or mycophenolate sodium was used in 486 of 491 recipients, or 98.98%. Tacrolimus reached 75.36% of the cohort and rose from 60.4% to 87.2% between the two periods. Cyclosporine fell from 37.8% to 12.8%. Induction therapy rose from 47.9% to 77.7% of recipients, which means the cohort is far too uniform on mycophenolate to test it as a risk factor on its own.
How common are carbapenemase-producing bacteria in transplant urinary infection
Fourteen episodes involved carbapenemase-producing Klebsiella pneumoniae, and ten of those carried a VIM metallo-beta-lactamase. Almost all appeared in 2022 with one exception. The absolute number is small, but the concentration in a single year and the enzyme class both matter for empiric prescribing.
Does cytomegalovirus infection raise urinary infection risk after transplant
The association was borderline rather than established. Cytomegalovirus infection appeared in 38.8% of patients with symptomatic urinary infection against 29.5% of those without, p = 0.057. Separately, documented cytomegalovirus infection fell from 39.2% to 25.9% of recipients over the decade, suggesting that antiviral prophylaxis and monitoring did change outcomes.
What antibiotic prophylaxis is used after kidney transplantation
Perioperative ceftriaxone for four days, followed by trimethoprim and sulfamethoxazole at 80 and 400 mg daily by mouth for six months. The main purpose is preventing Pneumocystis pneumonia, though the trimethoprim component also suppresses many uropathogens. Urine cultures were taken weekly during the first month after transplantation.
How many transplant recipients develop a urinary tract infection in the first year
Between 36% and 41% of recipients, depending on the period. The earlier period recorded 89 of 217 recipients, or 41%, and the later one 98 of 274, or 36%, with p = 0.26. Of the 491 recipients analyzed, 187 had at least one episode, producing 448 episodes in total across ten years, and 121 of those patients had symptomatic rather than asymptomatic infection.
Which urinary syndromes are dominated by Klebsiella pneumoniae
Asymptomatic bacteriuria, cystitis, and acute graft pyelonephritis were all dominated by Klebsiella pneumoniae in the later period. Urosepsis was the exception and remained dominated by Escherichia coli. That split is the basis for choosing different empiric coverage in septic and non-septic presentations.
Did infection rates fall as hospital stays shortened
Infection volume stayed roughly flat while stays shortened, from a mean of 20.13 days to 16.89 days, p under 0.001. Length of stay remained an independent risk factor in both models, with an adjusted odds ratio of 1.05 per day and an adjusted incidence rate ratio of 1.03 per day. Shorter stays did not translate into fewer infections over this decade.

Comments are closed